Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 1, 2008 Brian Lawler	Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
The Motley Fool May 22, 2008 Brian Lawler	Enzon Shareholders Steal the Show A shareholder tussle overshadows clinical trial data.
The Motley Fool May 29, 2008 Brian Lawler	Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors.
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool December 13, 2007 Brian Lawler	Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers.
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool September 11, 2008 Brian Lawler	ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.
The Motley Fool November 8, 2007 Brian Lawler	Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note.
The Motley Fool October 25, 2006 Brian Lawler	Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool September 22, 2008 Brian Lawler	Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems.
The Motley Fool April 16, 2009 Brian Orelli	Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders?
The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
The Motley Fool May 19, 2008 Brian Orelli	What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase.
The Motley Fool January 5, 2010 Brian Orelli	Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.
The Motley Fool April 8, 2010 Brian Orelli	Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult.
The Motley Fool June 30, 2010 Ryan McBride	Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately.
The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
The Motley Fool June 8, 2010 Ryan McBride	Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks.
The Motley Fool December 16, 2009 Brian Orelli	No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool May 26, 2009 Brian Orelli	Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool February 17, 2010 Anders Bylund	Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney?
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
BusinessWeek October 29, 2007 Hamm & Grover	Tech Gets the Icahn Treatment Carl Icahn is shaking up the landscape in Silicon Valley as companies' revenue growth slows.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool November 8, 2005 Rich Duprey	Fairmont's Fair Game for Icahn Financier takes a stake in the luxury resort chain Fairmont Hotels & Resorts to maximize undervalued assets. These plans should really come as no surprise to Fairmont investors.
The Motley Fool September 4, 2009 Brian Orelli	Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share.
The Motley Fool May 31, 2005 Tom Taulli	The Icahn Effect Carl Icahn has spread fear throughout corporate boardrooms. Now hedge fund Relational Investors looks like an Icahn wannabe.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool May 16, 2008 Mac Greer	Fool Video: Icahn Bares His Teeth, Craig's Cyst, and 5 Stocks Approaching Greatness Can Craigslist delete eBay? Will Icahn deliver for Microsoft? These questions are discussed in this video.